Philippe Saiag1, Philippe Aegerter2, Dominique Vitoux2, Celeste Lebbé2, Pierre Wolkenstein2, Nicolas Dupin2, Vincent Descamps2, Selim Aractingi2, Elisa Funck-Brentano2, Philippe Autier2, Miruna Dragomir2, Mathieu Boniol2. 1. Université de Versailles St-Quentin, EA 4340, F-92104 Boulogne-Billancourt, France (PS, EFB); AP-HP, Hôpital Ambroise Paré, Service de Dermatologie Générale et Oncologique, F-92104 Boulogne-Billancourt, France (PS, EFB); Université de Versailles St-Quentin, UMR-S 1168, Saint Quentin-en-Yvelines, France (PA); INSERM, U1168 F-94807, Villejuif, France (PA); AP-HP, Hôpital Ambroise Paré, Unité de recherche clinique et département de santé Publique, F-92104 Boulogne-Billancourt, France (PA); APHP, service de Biochimie, Hôpital Saint-Louis, F-75010 Paris, France (DV); APHP, service de Dermatologie, Hôpital Saint-Louis, F-75010 Paris, France (CL); Université Paris Diderot, F-75010 Paris, France (CL, VD); APHP, service de Dermatologie, Hôpital Henri Mondor, F-94000 Créteil, France (PW); Université Paris-Est Créteil, F-94000 Créteil, France (PW); APHP, service de Dermatologie, Pavillon Tarnier, Hôpital Cochin, F-75014 Paris, France (ND, SA); Université Paris Descartes, F-75014 Paris, France (ND, SA); APHP, service de Dermatologie, Hôpital Bichat, F-75018 Paris, France (VD); Strathclyde Institute for Global Public Health at iPRI, F-69000 Lyon, France (PA, MB); International Prevention Research Institute (iPRI), F-69000 Lyon, France (PA, MD, MB). philippe.saiag@uvsq.fr. 2. Université de Versailles St-Quentin, EA 4340, F-92104 Boulogne-Billancourt, France (PS, EFB); AP-HP, Hôpital Ambroise Paré, Service de Dermatologie Générale et Oncologique, F-92104 Boulogne-Billancourt, France (PS, EFB); Université de Versailles St-Quentin, UMR-S 1168, Saint Quentin-en-Yvelines, France (PA); INSERM, U1168 F-94807, Villejuif, France (PA); AP-HP, Hôpital Ambroise Paré, Unité de recherche clinique et département de santé Publique, F-92104 Boulogne-Billancourt, France (PA); APHP, service de Biochimie, Hôpital Saint-Louis, F-75010 Paris, France (DV); APHP, service de Dermatologie, Hôpital Saint-Louis, F-75010 Paris, France (CL); Université Paris Diderot, F-75010 Paris, France (CL, VD); APHP, service de Dermatologie, Hôpital Henri Mondor, F-94000 Créteil, France (PW); Université Paris-Est Créteil, F-94000 Créteil, France (PW); APHP, service de Dermatologie, Pavillon Tarnier, Hôpital Cochin, F-75014 Paris, France (ND, SA); Université Paris Descartes, F-75014 Paris, France (ND, SA); APHP, service de Dermatologie, Hôpital Bichat, F-75018 Paris, France (VD); Strathclyde Institute for Global Public Health at iPRI, F-69000 Lyon, France (PA, MB); International Prevention Research Institute (iPRI), F-69000 Lyon, France (PA, MD, MB).
Abstract
BACKGROUND: A low 25-hydroxyvitamin D3 (25(OH)D3) serum concentration at melanoma diagnosis might be associated with worse survival. We prospectively studied the prognostic value of 25(OH)D3 at diagnosis and during follow-up. METHODS: MelanCohort is a cohort of invasive melanoma patients. Serum 25(OH)D3 was measured by mass spectrometry and standardized on month of blood drawn, age, sex, and body mass index (BMI). Role of 25(OH)D3 levels and risk of relapse was analyzed in a Cox proportional hazards model adjusting for age, sex, BMI, and American Joint Committee on Cancer (AJCC) stage. All statistical tests were two-sided. RESULTS: One thousand one hundred seventy-one patients were included. 25(OH)D3 levels at diagnosis (median = 49.0 nmol/L) were inversely correlated with prognostic factors such as AJCC stage (P < .001 Kruskal-Wallis), Breslow's thickness (P < .001 Spearman correlation), and ulceration (P < .001 Kruskal-Wallis), but not with risk of relapse. Changes in 25(OH)D3 levels during follow-up were associated with worse prognosis: With a third quartile Q3 of average change per year (-0.30 to 4.60 nmol/L/Y) used as reference, hazard ratios for the first, second, and fourth quarters were 1.94 (95% confidence interval [CI] = 1.36 to 2.76), 1.23 (95% CI = 0.85 to 1.78), and 1.61 (95% CI = 1.14 to 2.28), respectively. In sensitivity analyses, no changes were observed either by AJCC stage, number of 25(OH)D3 measures performed, or by 25(OH)D3 level at baseline. No evidence of reverse causation was identified. Analyses performed on overall survival yielded similar results. CONCLUSIONS: We show that 25(OH)D3 variation during follow-up is an independent melanoma prognostic marker, but not its level at diagnosis. Previously reported associations between low 25(OH)D3 level at diagnosis and poor prognosis seem to be due to insufficient adjustment for prognostic factors.
BACKGROUND: A low 25-hydroxyvitamin D3 (25(OH)D3) serum concentration at melanoma diagnosis might be associated with worse survival. We prospectively studied the prognostic value of 25(OH)D3 at diagnosis and during follow-up. METHODS: MelanCohort is a cohort of invasive melanomapatients. Serum 25(OH)D3 was measured by mass spectrometry and standardized on month of blood drawn, age, sex, and body mass index (BMI). Role of 25(OH)D3 levels and risk of relapse was analyzed in a Cox proportional hazards model adjusting for age, sex, BMI, and American Joint Committee on Cancer (AJCC) stage. All statistical tests were two-sided. RESULTS: One thousand one hundred seventy-one patients were included. 25(OH)D3 levels at diagnosis (median = 49.0 nmol/L) were inversely correlated with prognostic factors such as AJCC stage (P < .001 Kruskal-Wallis), Breslow's thickness (P < .001 Spearman correlation), and ulceration (P < .001 Kruskal-Wallis), but not with risk of relapse. Changes in 25(OH)D3 levels during follow-up were associated with worse prognosis: With a third quartile Q3 of average change per year (-0.30 to 4.60 nmol/L/Y) used as reference, hazard ratios for the first, second, and fourth quarters were 1.94 (95% confidence interval [CI] = 1.36 to 2.76), 1.23 (95% CI = 0.85 to 1.78), and 1.61 (95% CI = 1.14 to 2.28), respectively. In sensitivity analyses, no changes were observed either by AJCC stage, number of 25(OH)D3 measures performed, or by 25(OH)D3 level at baseline. No evidence of reverse causation was identified. Analyses performed on overall survival yielded similar results. CONCLUSIONS: We show that 25(OH)D3 variation during follow-up is an independent melanoma prognostic marker, but not its level at diagnosis. Previously reported associations between low 25(OH)D3 level at diagnosis and poor prognosis seem to be due to insufficient adjustment for prognostic factors.
Authors: Elizabeth Loehrer; Rebecca A Betensky; Edward Giovannucci; Li Su; Andrea Shafer; Bruce W Hollis; David C Christiani Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-06-11 Impact factor: 4.254
Authors: Irene Orlow; Yang Shi; Peter A Kanetsky; Nancy E Thomas; Li Luo; Sergio Corrales-Guerrero; Anne E Cust; Lidia Sacchetto; Roberto Zanetti; Stefano Rosso; Bruce K Armstrong; Terence Dwyer; Alison Venn; Richard P Gallagher; Stephen B Gruber; Loraine D Marrett; Hoda Anton-Culver; Klaus Busam; Colin B Begg; Marianne Berwick Journal: Pigment Cell Melanoma Res Date: 2017-11-05 Impact factor: 4.693
Authors: Andrzej T Slominski; Anna A Brożyna; Cezary Skobowiat; Michal A Zmijewski; Tae-Kang Kim; Zorica Janjetovic; Allen S Oak; Wojciech Jozwicki; Anton M Jetten; Rebecca S Mason; Craig Elmets; We Li; Robert M Hoffman; Robert C Tuckey Journal: J Steroid Biochem Mol Biol Date: 2017-07-01 Impact factor: 4.292
Authors: Jo Steinson Stenehjem; Tom K Grimsrud; Judith R Rees; Linda Vos; Ronnie Babigumira; Marit B Veierød; Trude Eid Robsahm Journal: BMJ Open Date: 2017-06-21 Impact factor: 2.692
Authors: J De Smedt; S Van Kelst; V Boecxstaens; M Stas; K Bogaerts; D Vanderschueren; C Aura; K Vandenberghe; D Lambrechts; P Wolter; O Bechter; A Nikkels; T Strobbe; G Emri; V Marasigan; M Garmyn Journal: BMC Cancer Date: 2017-08-23 Impact factor: 4.430
Authors: Dmitriy Timerman; Melissa McEnery-Stonelake; Cara J Joyce; Vinod E Nambudiri; F Stephen Hodi; Elizabeth B Claus; Nageatte Ibrahim; Jennifer Y Lin Journal: Oncotarget Date: 2017-01-24
Authors: Astrid Lipplaa; Ricardo Fernandes; Andrea Marshall; Paul Lorigan; Janet Dunn; Kevin A Myers; Emily Barker; Julia Newton-Bishop; Mark R Middleton; Pippa G Corrie Journal: Br J Cancer Date: 2018-07-23 Impact factor: 7.640